Geriatric trauma G-60 falls with XXXX : A pilot study of acute @entity158 management using femoral nerve fascia iliac blocks.

@entity1 @entity174 @entity173 @entity1576 @entity158 @entity933 @entity616
BACKGROUND: @entity173 due to falls cause significant morbidity and mortality among geriatric @entity1 . A significant unmet need is an optimal @entity158 management strategy. Consequently, @entity1 are treated with standard analgesic care (SAC) regimens, which deliver high narcotic doses. However, narcotics are associated with @entity933 as well as gastrointestinal and @entity1576 risks. The purpose of this pilot study was to determine the safety and effectiveness of ultrasound-guided continuous compartmental fascia @entity616 (CFIB) in @entity1 60 years or older with @entity173 in comparison with SAC alone. METHODS: We performed a retrospective study of 108 @entity1 60 years or older, with acute @entity158 secondary to hip @entity174 (2012-2013). @entity1 variables were age, sex, comorbidities, and Injury Severity Score (ISS). Primary outcome was @entity158 scores; secondary outcomes included hospital length of stay, discharge disposition, morbidity, and mortality. Statistical analysis was performed using (IBM SPSS version 22). For group comparison (SAC vs. SAC + CFIB) median test, repeated-measures analysis and Student's t test of transformed @entity158 scores were used. RESULTS: Sixty-four @entity1 received SAC only, and 44 @entity1 received SAC + CFIB. Each CFIB placement was successful on first attempt without complications. Median time from emergency department arrival to block placement was 12.5 hours (interquartile range, 4-22 hours). @entity1 who received SAC + CFIB had significantly lower @entity158 score ratings than @entity1 treated with SAC alone. There were no differences in inpatient morbidity and mortality rates. @entity1 treated with SAC + CFIB were discharged home more often (p < 0.05). CONCLUSION: Ultrasound-guided CFIB is safe, practical, and readily integrated into the G-60 service for improved @entity158 management of @entity173 . We are now conducting a prospective randomized control trial to confirm our observations. LEVEL OF EVIDENCE: Therapeutic study, level IV.
